Clinical Trial Update: A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluated the effectiveness and safety of immediate-release galantamine in mild-to-moderate Alzheimer's disease; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Galantamine IR (galantamine)

Snippet

Sponsor: Xian-Janssen Pharmaceutical Ltd. | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED